AU2022283816A1 - Protease inhibitors as antivirals - Google Patents
Protease inhibitors as antivirals Download PDFInfo
- Publication number
- AU2022283816A1 AU2022283816A1 AU2022283816A AU2022283816A AU2022283816A1 AU 2022283816 A1 AU2022283816 A1 AU 2022283816A1 AU 2022283816 A AU2022283816 A AU 2022283816A AU 2022283816 A AU2022283816 A AU 2022283816A AU 2022283816 A1 AU2022283816 A1 AU 2022283816A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mixture
- alkyl
- tautomers
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195930P | 2021-06-02 | 2021-06-02 | |
| US63/195,930 | 2021-06-02 | ||
| US202163275113P | 2021-11-03 | 2021-11-03 | |
| US63/275,113 | 2021-11-03 | ||
| PCT/US2022/031815 WO2022256434A1 (en) | 2021-06-02 | 2022-06-01 | Protease inhibitors as antivirals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022283816A1 true AU2022283816A1 (en) | 2024-01-04 |
Family
ID=82321542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022283816A Pending AU2022283816A1 (en) | 2021-06-02 | 2022-06-01 | Protease inhibitors as antivirals |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11753373B2 (https=) |
| EP (1) | EP4347034A1 (https=) |
| JP (1) | JP2024522990A (https=) |
| KR (1) | KR20240057384A (https=) |
| AU (1) | AU2022283816A1 (https=) |
| BR (1) | BR112023025358A2 (https=) |
| CA (1) | CA3220847A1 (https=) |
| IL (1) | IL308694A (https=) |
| MX (1) | MX2023014307A (https=) |
| TW (1) | TW202313567A (https=) |
| WO (1) | WO2022256434A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220033383A1 (en) * | 2020-07-20 | 2022-02-03 | Enanta Pharmaceuticals, Inc. | Functionalized peptides as antiviral agents |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CA3200437A1 (en) * | 2020-12-01 | 2022-06-09 | Arun K. Ghosh | Compounds for the treatment of sars |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| WO2022256434A1 (en) | 2021-06-02 | 2022-12-08 | ACEA Therapeutics, Inc. | Protease inhibitors as antivirals |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN118302421A (zh) * | 2021-11-26 | 2024-07-05 | 海南先声药业有限公司 | 一种吡咯烷类抗病毒化合物 |
| US12145941B2 (en) | 2021-12-08 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| TW202334123A (zh) * | 2021-12-31 | 2023-09-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | 用於預防和治療冠狀病毒感染的化合物及其偶聯物和方法 |
| CN118451090A (zh) * | 2022-01-13 | 2024-08-06 | 海南先声药业有限公司 | 一种酰胺类抗病毒化合物 |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN116535460A (zh) * | 2023-04-28 | 2023-08-04 | 中国人民解放军军事科学院军事医学研究院 | 一类含硫拟肽类化合物及其制备方法和用途 |
| WO2024237816A1 (ru) * | 2023-05-12 | 2024-11-21 | Общество С Ограниченной Ответственностью "Промомед Рус" | Новые производные азабициклогексана |
| CN119306790A (zh) * | 2023-07-13 | 2025-01-14 | 深圳市塔吉瑞生物医药有限公司 | 酰胺衍生物及其组合物及用途 |
| EP4686470A1 (en) | 2024-08-01 | 2026-02-04 | Ospedale San Raffaele S.r.l. | Macrocyclic peptidomimetics as antiviral agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1704142A4 (en) * | 2003-12-31 | 2008-08-20 | Taigen Biotechnology Co Ltd | PROTEASE INHIBITORS |
| WO2005113580A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| WO2006061714A2 (en) * | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| CN110818691A (zh) | 2018-08-09 | 2020-02-21 | 中国科学院上海药物研究所 | 酮酰胺类化合物及其制备方法、药物组合物和用途 |
| CN113939267B (zh) | 2019-06-05 | 2025-11-11 | 法国特种经营公司 | 口腔护理组合物 |
| BR112021024310A2 (pt) | 2019-06-05 | 2022-02-15 | Univ Emory | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus |
| WO2021205296A1 (en) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Method of treating covid-19 |
| AU2021254045A1 (en) * | 2020-04-10 | 2022-10-13 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
| US11124497B1 (en) * | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| BR112022021381A2 (pt) * | 2020-04-23 | 2022-12-06 | Purdue Research Foundation | Compostos para o tratamento de sars |
| BR112021023814A2 (pt) * | 2020-06-09 | 2022-12-20 | Pardes Biosciences Inc | Inibidores de proteases de cisteína e métodos de uso das mesmas |
| MX2023001756A (es) * | 2020-08-13 | 2023-05-04 | Enanta Pharm Inc | Peptidos funcionalizados como agentes antivirales. |
| US11351149B2 (en) * | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| WO2022256434A1 (en) | 2021-06-02 | 2022-12-08 | ACEA Therapeutics, Inc. | Protease inhibitors as antivirals |
-
2022
- 2022-06-01 WO PCT/US2022/031815 patent/WO2022256434A1/en not_active Ceased
- 2022-06-01 CA CA3220847A patent/CA3220847A1/en active Pending
- 2022-06-01 JP JP2023574150A patent/JP2024522990A/ja active Pending
- 2022-06-01 TW TW111120433A patent/TW202313567A/zh unknown
- 2022-06-01 US US17/830,185 patent/US11753373B2/en active Active
- 2022-06-01 BR BR112023025358A patent/BR112023025358A2/pt unknown
- 2022-06-01 IL IL308694A patent/IL308694A/en unknown
- 2022-06-01 EP EP22735725.8A patent/EP4347034A1/en active Pending
- 2022-06-01 KR KR1020237045446A patent/KR20240057384A/ko active Pending
- 2022-06-01 MX MX2023014307A patent/MX2023014307A/es unknown
- 2022-06-01 AU AU2022283816A patent/AU2022283816A1/en active Pending
-
2023
- 2023-06-15 US US18/210,555 patent/US11987554B2/en active Active
-
2024
- 2024-04-22 US US18/642,453 patent/US20250122153A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250122153A1 (en) | 2025-04-17 |
| WO2022256434A1 (en) | 2022-12-08 |
| US20230322668A1 (en) | 2023-10-12 |
| TW202313567A (zh) | 2023-04-01 |
| US11753373B2 (en) | 2023-09-12 |
| CA3220847A1 (en) | 2022-12-08 |
| BR112023025358A2 (pt) | 2024-02-27 |
| IL308694A (en) | 2024-01-01 |
| US20230026438A1 (en) | 2023-01-26 |
| JP2024522990A (ja) | 2024-06-25 |
| EP4347034A1 (en) | 2024-04-10 |
| MX2023014307A (es) | 2024-04-05 |
| KR20240057384A (ko) | 2024-05-02 |
| US11987554B2 (en) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022283816A1 (en) | Protease inhibitors as antivirals | |
| TWI846527B (zh) | 一種多功能化合物、其製備方法及其在醫藥上的應用 | |
| RU2197477C2 (ru) | Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию | |
| US8618163B2 (en) | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity | |
| ES3045115T3 (en) | Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof | |
| SK15462000A3 (sk) | Substituované pyrolidínové hydroxamáty ako inhibítory metaloproteázy | |
| CN102036956A (zh) | 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法 | |
| CA3101626A1 (en) | Cannabinoids and uses thereof | |
| KR20150130392A (ko) | 구아니디노벤조산 에스테르 화합물 | |
| ES2615052T3 (es) | Compuesto de benzotiazolona | |
| HRP20000532A2 (en) | Novel naphthyl-substituted and anilide-substituted sulfonamides | |
| CN102066345B (zh) | *唑烷衍生物作为nmda拮抗剂 | |
| ZA200602888B (en) | Compounds and methods for treating dyslipidemia | |
| JP2006527209A (ja) | アシル化及び非−アシル化イミダゾ[2,1−b]−1,3,4−チアジアゾール−2−スルホンアミド及びその使用 | |
| EP1496053B1 (en) | Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative | |
| CA3217790A1 (en) | Fatty acid amide hydrolase (faah) cleavable prodrugs of brain targeting actives and combination with peripherally restricted faah inhibitors | |
| US20240400508A1 (en) | Alkyl-substituted derivatives of mesembrine and mesembrenone and therapeutic uses thereof | |
| NZ260063A (en) | Aromatic derivatrives of 2,4-diamino-3-hydroxy carboxylic acid amides; and medicaments thereof | |
| CN117769541A (zh) | 作为抗病毒剂的蛋白酶抑制剂 | |
| JPWO2005061492A1 (ja) | 含窒素複素環化合物およびそれらを有効成分とする薬剤 | |
| TW202100146A (zh) | 用於治療高血壓或心衰竭的化合物及包含其之組成物 | |
| CN101443315B (zh) | 作为p2x7调节剂的双环杂芳基化合物及其应用 | |
| ES2642003T3 (es) | Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 | |
| WO2026008076A1 (zh) | 含一氧化氮供体的黄酮类衍生物 | |
| HK40130194A (zh) | 含一氧化氮供体的黄酮类衍生物 |